PRODUCT INFORMATION

PX-13-17OH

Item No. 21203

CAS Registry No.: 884539-95-1
Formal Name: (1E,4S,4aR,5R,6aS,7S,9aR)-5-(acetyloxy)-1-[[[3-(dimethylamino)propyl]methylamino]methylene]-4a,5,6,6a,7,8,9,9a-octahydro-7,11-dihydroxy-4-(methoxymethyl)-4a,6a-dimethyl-cyclopenta[5,6]naphtho[1,2-c]pyran-2,10(1H,4H)-dione
MF: $C_{29}H_{42}N_2O_8$
FW: 546.7
Purity: ≥98%
UV/Vis.: λ_{max}: 251, 319, 407 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

PX-13-17OH is supplied as a crystalline solid. A stock solution may be made by dissolving the PX-13-17OH in the solvent of choice, which should be purged with an inert gas. PX-13-17OH is soluble in DMSO.

Description

PX-13-17OH is a PI3K inhibitor.[1] It selectively inhibits PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ (IC_{50}s = 6.4, 13, 8, and 11 nM, respectively) over mTOR (IC_{50} = 2.9 µM). PX-13-17OH is greater than 420-fold selective for PI3K in a panel of 20 lipid and protein kinases. PX-13-17OH inhibits phosphorylation of Akt and S6 kinase (S6K) in PTEN-negative U87MG cells when used at concentrations ranging from 0.03 to 1 µg/ml. It inhibits tumor growth in a U87MG mouse xenograft model when administered at doses ranging from 2.5 to 10 mg/kg.

References

1. Zask, A., Kaplan, J., Toral-Barza, L., *et al.* Synthesis and structure-activity relationships of ring-opened 17-hydroxywortmannins: Potent phosphoinositide 3-kinase inhibitors with improved properties and anticancer efficacy. *J. Med. Chem.* **51(5),** 1319-1323 (2008).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM